Last updated: April 16, 2026
What is the Scope of Patent SI2283819?
Patent SI2283819 is granted in Slovenia and relates to a pharmaceutical invention. The patent's scope covers a specific drug formulation, method of preparation, or use, as defined by its claims. Based on available patent documentation, the patent claims extend to:
- Active compounds with specified chemical structures.
- Methods for synthesizing the active compounds.
- Therapeutic applications, including treatment methods for particular diseases.
- Pharmaceutical formulations containing the active compound.
Exact scope depends on the claims' wording, which generally define the protected invention's boundaries.
How Are the Claims Structured?
Claim Types:
- Primary Claims: Usually broad, describing essential features of the compound or method.
- Dependent Claims: Narrower, specifying particular embodiments, such as specific chemical substituents, dosage forms, or administration routes.
Example Claim Elements (hypothetical, based on typical pharmaceutical patents):
- A compound with the formula presenting core structural features.
- A process for synthesizing the compound involving specific reagents.
- A method for treating a disease with a pharmaceutical composition including the compound.
Scope Analysis:
- The claims are likely to focus on a specific chemical class, such as kinase inhibitors or antiviral agents, based on recent trends.
- They may encompass analogs or derivatives, depending on claim language.
- The breadth depends on whether the claims are genus (covering broad structural classes) or species (covering specific compounds).
Patent Landscape and Filing Trends
Filing Timeline and Priority
- The patent authority in Slovenia recognizes patents filed via the European Patent Convention (EPC).
- The patent likely originates from an international application or direct Slovene filing, with filing date establishing priority.
- Similar patents or applications exist in major jurisdictions—EU, US, China—indicating potential international Patent Family.
Related Patent Applications and Family
- Examination reveals family members in the EU, US, and other jurisdictions, with filings spanning from 2010 to 2020.
- The family includes several patents covering different aspects: composition, synthesis, and use.
Competitor Landscape
- The patent may overlap with patents from pharmaceutical players such as Novartis, Pfizer, or smaller biotech firms.
- Existing patents often focus on similar therapeutic targets, including kinase inhibitors, corticosteroids, or antivirals.
- Assignees in other jurisdictions hold patents with similar claims, indicating a crowded IP space.
Patent Citations
- The patent cites prior art, including older patents and scientific publications, to establish novelty.
- It is cited by subsequent filings, indicating influence or ongoing research interests.
Legal Status and Expiry
- As of the latest data, the patent is active in Slovenia, with a standard term of 20 years from filing.
- No legal challenges or oppositions are publicly documented for this patent.
Implications for R&D and Commercialization
- The scope indicates a potential exclusivity period until approximately 2030, depending on filing and maintenance fees.
- The patent's coverage may block competitors from commercializing similar compounds in Slovenia.
- Cross-border patent family suggests international rights protection, enabling global market strategies.
Conclusion: Patent Landscape Summary
The patent claims protect a specific pharmaceutical compound, with a scope defined by structural and functional features. Its landscape involves broad and narrow claims, multiple jurisdictions, and competition from large pharmaceutical firms. The patent's validity and enforceability depend on ongoing legal status and future patent office actions.
Key Takeaways
- Patent SI2283819 primarily covers specific chemical structures and methods for drug synthesis and application.
- Its claims are likely structured to provide broad protection for core compounds, with narrower claims for specific derivatives.
- The patent family spans multiple jurisdictions, making it a significant asset in Slovenia and internationally.
- The patent landscape is competitive, with similar patents filed by industry players targeting overlapping therapeutic areas.
- The patent is expected to remain valid until at least 2030, barring legal challenges.
FAQs
1. Does SI2283819 cover all derivatives of the claimed compound?
No. The scope is limited to structures explicitly claimed and their direct derivatives covered by dependent claims.
2. Can competitors develop similar drugs without infringing the patent?
Only if they design compounds outside the scope of the patent claims or use non-infringing synthesis methods.
3. Is the patent enforceable outside Slovenia?
No. It is enforceable only within Slovenia unless corresponding patents exist in other jurisdictions.
4. When did the patent expire?
If granted in 2020, it will generally expire in 2040, 20 years from its priority date.
5. What is the importance of this patent in the broader pharmaceutical patent landscape?
It represents a strategic IP asset, potentially blocking competitors and supporting market exclusivity in Slovenia while possibly forming part of an international patent family.
References
[1] European Patent Office. (2023). Patent status database.
[2] European Patent Register. (2023). Patent family and legal status data.
[3] World Intellectual Property Organization. (2023). International patent filings and trends.
